Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
Top Page
Opyl Ltd.
(Sydney:PKY)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.05
â–²(70.00% Upside)
Action:ReiteratedDate:04/30/26
The score is primarily held back by very weak financials (shrinking revenue, persistent losses, negative equity, and ongoing cash burn). Technicals provide some offset due to strong upward momentum above key moving averages, but the extremely overbought RSI raises pullback risk. Valuation provides limited support given a negative P/E and no dividend yield data.
Positive Factors
AI/ML focus in life sciences
Opyl’s core focus on AI/ML for clinical trials aligns with a durable structural trend toward data-driven drug development. That specialization supports a large addressable market, potential defensibility via proprietary models/data, and long-term relevance to biopharma customers if commercial execution improves.
Negative Factors
Severe revenue decline
An ~86% year-over-year revenue collapse is a structural red flag: it undermines scale economics, weakens pricing power, and impedes investment in product and sales. Sustained top-line decline makes it harder to prove product-market fit to enterprise customers and to build durable margins over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
AI/ML focus in life sciences
Opyl’s core focus on AI/ML for clinical trials aligns with a durable structural trend toward data-driven drug development. That specialization supports a large addressable market, potential defensibility via proprietary models/data, and long-term relevance to biopharma customers if commercial execution improves.
Read all positive factors
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$31.57M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Opyl Ltd. Business Overview & Revenue Model
Company Description
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success predict...
How the Company Makes Money
Opyl’s revenue model is based on commercialising its technology and platforms through business-to-business arrangements. Key potential revenue streams include (i) subscription or licensing fees for access to its software platforms and analytics ca...
Opyl Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.95K | 27.78K | 397.64K | 397.64K | 617.91K | 902.41K |
| Gross Profit | -490.89K | -778.89K | -1.40M | -1.86M | -930.36K | -809.62K |
| EBITDA | -1.89M | -1.66M | -2.68M | -1.70M | -2.27M | -1.14M |
| Net Income | -1.44M | -1.45M | -3.13M | -3.13M | -1.73M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 881.60K | 513.28K | 411.60K | 411.60K | 709.58K | 979.22K |
| Cash, Cash Equivalents and Short-Term Investments | 580.84K | 436.90K | 374.64K | 452.88K | 786.33K | 2.32M |
| Total Debt | 0.00 | 411.73K | 0.00 | 300.00K | 300.00K | 0.00 |
| Total Liabilities | 356.22K | 781.65K | 501.76K | 501.76K | 712.21K | 314.75K |
| Stockholders Equity | 525.39K | -268.37K | -90.16K | -403.59K | 267.01K | 2.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.12M | -1.29M | -2.07M | -1.37M | -1.53M | -918.13K |
| Operating Cash Flow | -1.12M | -1.28M | -2.06M | -1.36M | -1.52M | -903.65K |
| Investing Cash Flow | -332.70K | -334.02K | -17.71K | -2.22K | -2.22K | -14.48K |
| Financing Cash Flow | 1.44M | 1.35M | 2.00M | 1.03M | 1.03M | 2.43M |
Opyl Ltd. Technical Analysis
Positive
0.03
Price Trends
0.02
Positive
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Negative
70.94
Negative
91.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PKY, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 70.94 is Negative, neither overbought nor oversold. The STOCH value of 91.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PKY.
Opyl Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$31.57M | -1.71 | -1122.02% | ― | ― | ― | |
46 Neutral | AU$15.55M | -2.48 | -578.72% | ― | 43.55% | 26.03% | |
43 Neutral | AU$66.35M | -6.64 | -59.96% | ― | ― | ― | |
41 Neutral | AU$4.23M | -1.98 | 20.02% | ― | -5.76% | 8.00% | |
41 Neutral | AU$9.07M | -0.96 | 152.58% | ― | -57.91% | -9.02% |
* Healthcare Sector Average
AU:PKY
Opyl Ltd.
0.05
0.03
116.67%
AU:GLH
Global Health Limited
0.07
-0.02
-20.00%
AU:SHG
Singular Health Group Ltd
0.21
-0.08
-27.59%
AU:HIQ
HitIQ Limited
0.01
-0.02
-58.62%
AU:ICR
InteliCare Holdings Limited
0.03
0.02
150.00%
Opyl Ltd. Corporate Events
Pathkey expands agentic AI footprint with Chipforge deal and TrialKey wins
Apr 30, 2026
Pathkey’s March quarter update shows continued investment in developing TrialKey as a scalable, AI-driven tool for clinical trial design, adding a Criteria Optimiser that uses agentic AI workflows to generate and rank protocol options under ...
PathKey.AI links share price surge to confidential Chipforge acquisition talks
Apr 29, 2026
PathKey.AI has responded to an ASX price query after its shares rose from $0.03 to $0.046 and trading volumes spiked in late April. The company disclosed it has been in confidential talks to acquire Singapore-based Chipforge Pte Ltd, which holds a...
Pathkey.AI Shares Halted Ahead of Price Query Response and Acquisition News
Apr 27, 2026
Pathkey.AI has requested and been granted a trading halt on its securities by the ASX, with the suspension to remain in place until the earlier of 29 April 2026 or the release of a pending market announcement. The halt is tied to the company prepa...
Pathkey.AI switches share registry provider to Xcend
Mar 27, 2026
Pathkey.AI Ltd has announced a change in its share registry services, transferring responsibility from Automic Registry Services to Xcend Pty Ltd, effective 13 April 2026. Automic will cease as registry provider on 10 April 2026, with XCEND to man...
Pathkey.AI shifts registered office to Sydney CBD while maintaining operations
Mar 13, 2026
Pathkey.AI Ltd has relocated its registered office and principal place of business to Level 12, 347 Kent Street, Sydney, while confirming that all other company details remain unchanged. The move signals an administrative change rather than a stra...
Pathkey.ai Awards 4 Million Incentive Options to Director Shannon Robinson
Feb 9, 2026
Pathkey.ai Ltd has granted director Shannon Robinson 4 million unlisted options with an exercise price of A$0.03 and an expiry date of 20 August 2029, issued indirectly through Berger Investment Fund Pty Ltd. The options, which were granted for ni...
Pathkey.ai Issues 4 Million Unquoted Options Under Employee Incentive Scheme
Feb 9, 2026
Pathkey.ai Ltd has notified the market of the issue of new unquoted equity securities under its employee incentive scheme. The company’s filing confirms its status as an ASX-listed entity with the issuer code PKY, but provides no further ope...
Pathify.ai Director Increases Indirect Shareholding Through Placement
Feb 6, 2026
Pathify.ai Ltd has disclosed a change in director Paul Niardone’s interests, with the director’s relevant interest held indirectly through Trindis Pty Ltd. While the notice does not detail the company’s operations, it confirms Ni...
PathKey.AI lodges cleansing notice for new share issue
Feb 4, 2026
The company lodged a cleansing notice confirming the issuance of 252,473,552 fully paid ordinary shares, stating that the shares were issued without a prospectus and that the company remains compliant with its financial reporting and continuous di...
Pathkey.AI Seeks ASX Quotation for Over 10 Million New Shares
Feb 4, 2026
Pathkey.AI Ltd has applied to the Australian Securities Exchange for quotation of 10,195,580 new fully paid ordinary shares under its ASX code PKY. The application, lodged as an Appendix 2A on 4 February 2026 and linked to a shareholder resolution...
PathKey.AI Issues 175.5 Million Unquoted Options Across Three New Classes
Feb 4, 2026
PathKey.AI Ltd has notified the market of the issue of 175.5 million unquoted options in three new unlisted security classes, each with different exercise prices and maturities. The options, which are not intended to be quoted on the ASX, are exer...
PathKey.AI Seeks ASX Quotation for 48.7 Million Ordinary Shares
Feb 4, 2026
PathKey.AI Ltd has lodged an Appendix 2A with the ASX seeking quotation of 48,728,425 ordinary fully paid shares under the code PKY, formalising their admission to trading on the exchange. The move significantly expands the number of quoted securi...
Pathkey.ai Seeks Quotation for 5 Million New Shares
Feb 4, 2026
Pathkey.ai operates in the artificial intelligence and data analytics sector, delivering AI-driven solutions that support enterprise decision-making and workflow automation across its target markets. The company has applied to list 5 million new f...
Opyl Updates Proposed Securities Issue and Option Terms
Feb 4, 2026
Opyl Ltd (PATHKEY.AI Ltd, ASX: PKY) has lodged an updated Appendix 3B with the ASX outlining changes to a previously proposed issue of securities via a placement or similar capital-raising mechanism. The update revises the number and terms of opti...
Opyl Trims Share Placement to Sandton Capital Advisory
Feb 4, 2026
Opyl Ltd has updated its planned capital raise, scaling the issuance from 6.47 million to 5 million shares to Sandton Capital Advisory under Resolution 5, signaling a more targeted financing round aligned with its December 2025 shareholder approva...
Pathkey.ai Seeks ASX Quotation for 188.5 Million Shares
Feb 4, 2026
Pathkey.ai operates in the AI technology sector, developing advanced data-driven solutions tailored for enterprise applications across the Australian market. The company has lodged an Appendix 2A to list 188,549,547 fully paid ordinary shares on t...
Pathkey.ai Options Lapse, Trimming Potential Equity Dilution
Feb 3, 2026
Pathkey.ai Ltd has announced the cessation of 1,780,000 unexercised options, designated as PKYAA, which expired on 10 December 2025 at various prices and dates. The expiry reduces the pool of potential dilutive securities on issue, slightly simpli...
Pathkey Sharpens AI Strategy, Strengthens Board and Balance Sheet in December Quarter
Jan 30, 2026
In its December 2025 quarter update, Pathkey outlined a period of consolidation marked by a strategic review that refines its positioning as an applied AI company beyond healthcare while keeping TrialKey as its lead commercial platform. The compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.